Squamous cell lung carcinoma
MONDO:0005097A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.
Also known as: epidermoid cell carcinoma of lung, epidermoid cell carcinoma of the lung, epidermoid cell lung carcinoma, lung squamous cell carcinoma, squamous cell carcinoma of lung, squamous cell carcinoma of the lung, squamous cell lung cancer, squamous cell lung carcinoma
2924 clinical trials for this condition and its sub-types, 65 tagged with Squamous cell lung carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Squamous cell lung carcinoma
-
Non-small cell squamous lung carcinoma 83 trials · 88 incl. sub-types
1 sub-type
- Adenosquamous lung carcinoma 5 trials
-
Lung occult squamous cell carcinoma 0 trials
-
Can an oral drug R01 fight advanced lung, stomach, and esophageal cancers?
Disease control Not yet recruitingThis early-phase trial tests an oral drug called R01 in people with advanced squamous cell lung cancer, gastric cancer, or esophageal cancer that has progressed after standard treatment. The study aims to find the safest dose and check whether R01 can shrink tumors. Participants …
Phase 1 • Sponsor: Beijing Anjianxi Bio-Medical Technology Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can an app plus nicotine gum help hispanic smokers kick the habit?
Disease control Not yet recruitingThis phase III trial will enroll 854 Hispanic adults who smoke and want to quit. Participants will use the iCanQuit smartphone app, which teaches skills to manage cravings and prevent relapse. Half will also receive nicotine replacement therapy (gum, patch, or lozenge) to ease wi…
Phase 3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Two apps battle to help smokers kick the habit
Disease control Not yet recruitingThis study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…
Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…
Phase 2/3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New chatbot aims to help native americans kick the habit
Disease control Not yet recruitingThis study is testing two remote programs—a chatbot app called QuitBot and a text messaging service—to help American Indian and Alaska Native adults quit smoking. About 772 participants will be randomly assigned to one of the programs. The goal is to see which approach works bett…
Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can simulated High-Altitude breathing boost lung cancer treatment?
Disease control Not yet recruitingThis phase 2 trial tests whether adding intermittent hypoxic training (IHT) – short sessions of breathing low-oxygen air – to standard chemo-immunotherapy can improve outcomes for people with stage II-IIIA lung squamous cell carcinoma. About 60 participants will receive either st…
Phase 2 • Sponsor: zhang yi • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to stall advanced lung cancer
Disease control Not yet recruitingThis study tests whether adding a targeted chemoembolization procedure to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 participants who have already responded to initial treatment will be ran…
Phase 4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Vaping vs. smoking weed: which delivers THC faster?
Knowledge-focused Not yet recruitingThis study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Eye movements may reveal nicotine addiction in vapers
Knowledge-focused Not yet recruitingThis study aims to see how nicotine changes eye movements in people who use e-cigarettes. Researchers will measure things like how fast eyes move and how well they follow objects, along with blood nicotine levels and self-reported feelings. The goal is to find a more objective wa…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Blood test may predict who benefits from lung cancer combo therapy
Knowledge-focused Not yet recruitingThis study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before an…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC